Immunicom, Inc.

Immunicom, Inc. is a biotechnology company specializing in innovative immunotherapies through its proprietary Immunopheresis® platform—a therapeutic blood-filtering device designed to remove immune-suppressing barriers from circulation. The technology is engineered to treat cancer, inflammatory diseases, cardiovascular conditions, renal diseases, and autoimmune disorders by restoring immune system function outside the body. The company has received FDA Breakthrough Device Designation (2018) for cancer treatment and CE Mark approval in Europe for advanced, refractory triple-negative breast cancer. Immunicom is conducting global clinical trials in partnership with leading hospitals and maintains an active pipeline including LW-02 and EN-06 cartridge formulations targeting multiple cancer types and systemic diseases. The Immunopheresis approach aims to improve patient quality of life while reducing typical immunotherapy side effects.